Kolexia
Zerazhi Hacene Hématologie
Zerazhi Hacene
Hématologie
Centre Hospitalier D’Avignon
Avignon, France
86 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome à cellules du manteau Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Myélome multiple Lymphome T Polyglobulie primitive essentielle Polyglobulie

Collaborateurs

Voir plus
Chebrek Safia
Chebrek Safia
Centre Hospitalier D’Avignon, Avignon, France
Slama Borhane
Slama Borhane
Centre Hospitalier D’Avignon, Avignon, France
Boulat Olivier
Boulat Olivier
Centre Hospitalier D’Avignon, Avignon, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Janssen
5 collaboration(s)
Dernière en 2023
Abbvie
4 collaboration(s)
Dernière en 2023
Amgen
4 collaboration(s)
Dernière en 2023
Harris Interactive
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
IPA-LMC: Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
Essai Clinique (Centre Hospitalier D’Avignon)   29 novembre 2023
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia: Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Essai Clinique (University of Ulm)   29 novembre 2023
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
TRANSCRIPT: Transplantation After Complete Response In Patients With T-cell Lymphoma
Essai Clinique (Hospices Civils de Lyon)   26 septembre 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Annals of hematology   10 juin 2023